Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06587282 · ClinicalTrials.gov registry record · NA
PREEMIE: Study for Treatment of PDA in Premature Infants
A NA study of Patent Ductus Arteriosus (PDA), sponsored by Merit Medical Systems.
- Recruiting
- Registry status
- NA
- Development phase
- 55
- Enrollment target
- 10
- Study locations
NCT06587282: Recruiting NA study of Patent Ductus Arteriosus (PDA), sponsored by Merit Medical Systems.
NCT06587282 is a NA study of Patent Ductus Arteriosus (PDA) that is actively recruiting participants, run by Merit Medical Systems. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06587282, a NA study of Patent Ductus Arteriosus (PDA), is actively recruiting participants, sponsored by Merit Medical Systems.
- RECRUITING
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
- 10
- Study locations
Study Summary
This multicenter, single arm, prospective, non-randomized study is designed to evaluate the safety and effectiveness of The Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in pre-mature infants over a period of 6 months.
Primary Outcome
Composite rate of device-related Major Adverse Events (MAE) of interest through 30 days following the index procedure.
Conditions Studied
Interventions
- DEVICE Bloom Micro Occluder System
Study Locations (10)
California
- UC Davis Health - Sacramento
- UC San Diego-Rady Children's Hospital - San Diego
Florida
- Memorial Healthcare System-Joe DiMaggio Children's Hospital - Hollywood
- Nicklaus Children's Hospital - Miami
Georgia
- Children's Healthcare of Atlanta - Atlanta
Missouri
- Washington University-St. Louis Children's Hospital - St Louis
Ohio
- Nationwide Children's Hospital - Columbus
Tennessee
- Le Bonheur Children's Hospital - Memphis
Texas
- UT Southwestern Medical Center - Dallas
Wisconsin
- Herma Heart Institute-Children's Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2029-03 |
| Phase | NA |
What NCT06587282 shows while recruiting
NCT06587282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Patent Ductus Arteriosus (PDA) appearing as the primary indexed condition, and to 1 intervention - of which Bloom Micro Occluder System is the first listed.
NCT06587282 lists 10 locations in 8 states (California, Florida, Georgia).
Frequently Asked Questions
What is clinical trial NCT06587282 about?
NCT06587282 is a clinical study titled "PREEMIE: Study for Treatment of PDA in Premature Infants". This multicenter, single arm, prospective, non-randomized study is designed to evaluate the safety and effectiveness of The Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in pre-mature infants over a period of 6 months.
What is the current status of trial NCT06587282?
This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2025-03-06. Estimated completion is 2029-03.
What conditions does trial NCT06587282 study?
This clinical trial studies the following conditions: Patent Ductus Arteriosus (PDA).
What interventions are being tested in trial NCT06587282?
The interventions under investigation include: Bloom Micro Occluder System (DEVICE).
Who is sponsoring clinical trial NCT06587282?
This trial is sponsored by Merit Medical Systems, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06587282 being conducted?
This trial has 10 study locations across California, Florida, Georgia, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06587282's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI